Correction to: Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans (Hepatology, (2011), 54, 5, (1661-1678), 10.1002/hep.24539);Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans

Hepatology

Volumn 54, Issue 5, 2011, Pages 1661-1678

  Kim, Yeonghwan ^a   Jang, Miran ^a   Lim, Sangbin ^a   Won, Hyeran ^a   Yoon, Kyung Sik ^a   Park, Jae Hoon ^a   Kim, Hyo Jong ^a   Kim, Byung Ho ^a   Park, Won Sang ^a   Ha, Joohun ^a   Kim, Sung Soo ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHILIN B; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT;

EID: 80055063236     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.31061     Document Type: Erratum

References (39)

1. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-547.
2. Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT. Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci U S A 1991; 88: 1903-1907.
3. Kim J, Choi TG, Ding Y, Kim Y, Ha KS, Lee KH, et al. Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci 2008; 121: 3636-3648.
4. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111-122.
5. Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. HEPATOLOGY 2006; 43: 761-770.
6. Hanoulle X, Badillo A, Wieruszeski JM, Verdegem D, Landrieu I, Bartenschlager R, et al. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem 2009; 284: 13589-13601.
7. Fernandes F, Ansari IU, Striker R. cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One 2010; 5: e9815.
8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
9. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. HEPATOLOGY 2008; 48: 2047-2063.
10. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. HEPATOLOGY 1996; 23: 455-464.
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
12. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811.
13. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res 2007; 67: 854-855.
14. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-408.
16. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-191.
17. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-221.
18. Bandyopadhyay A, Ghoshal S, Mukherjee A. Genotoxicity testing of low-calorie sweeteners: aspartame, acesulfame-K, and saccharin. Drug Chem Toxicol 2008; 31: 447-457.
19. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20: 5197-5206.
20. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
21. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis. Nature 1998; 394: 485-490.
22. Waypa GB, Marks JD, Mack MM, Boriboun C, Mungai PT, Schumacker PT. Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ Res 2002; 91: 719-726.
23. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1: 401-408.
24. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
25. Bauer K, Kretzschmar AK, Cvijic H, Blumert C, Loffler D, Brocke-Heidrich K, et al. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene 2009; 28: 2784-2795.
26. Vollmer S, Kappler V, Kaczor J, Flugel D, Rolvering C, Kato N, et al. Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. HEPATOLOGY 2009; 50: 253-260.
27. Urbatsch IL, Sankaran B, Weber J, Senior AE. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 1995; 270: 19383-19390.
28. Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM, et al. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc Natl Acad Sci U S A 1998; 95: 162-166.
29. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999; 59: 3077-3083.
30. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A 1997; 94: 5667-5672.
31. Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001; 276: 2292-2298.
32. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2007; 2: e1364.
33. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, et al. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 2009; 10: 195-202.
34. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665.
35. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495.
36. Kaelin WG, Jr. ROS: really involved in oxygen sensing. Cell Metab 2005; 1: 357-358.
37. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 2008; 15: 660-666.
38. Dong Z, Venkatachalam MA, Wang J, Patel Y, Saikumar P, Semenza GL, et al. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 2001; 276: 18702-18709.
39. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480.